Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target

Vanda Pharmaceuticals has demonstrated a promising outlook driven by its potential revenue growth from tradipitant due to long-lived patent claims, which may extend well beyond the current projections. The approval status of milsaperidone is notably strengthened, with a 100% probability of approval in bipolar I disorder and schizophrenia and market exclusivity extending to 2044, highlighting a solid foundation for future innovation. Additionally, the recent positive results from the tradipitant study for nausea and vomiting prevention in conjunction with GLP-1 receptor agonists suggest significant demand potential, reinforcing the company’s commitment to addressing unmet medical needs in patient care.

Vanda Pharmaceuticals Inc faces significant risks that contribute to a negative outlook on its stock, including slower-than-expected market traction for its main revenue generators, Fanapt and Ponvory, and the threat of accelerated generic erosion affecting these products. Furthermore, negative developments in pricing, especially concerning Medicare reimbursements, along with potential regulatory setbacks in its late-stage pipeline candidates, raise additional concerns. The company also faces risks from possible adverse developments in mergers and acquisitions, medium- to long-term dilution risks, and a projected decline in tradipitant sales post-2030, all of which hinder confidence in its future financial performance.